Abstracts Archive - Page 2147 of 2425 - ACR Meeting Abstracts

Abstract Number: 1541 • 2013 ACR/ARHP Annual Meeting
Spinal Mobility Gets Impaired In a Fixed Order In Patients With Ankylosing Spondylitis: 12-Year OASIS Results
Sofia Ramiro¹, Robert Landewé², Désirée van der Heijde³, Carmen Stolwijk⁴, Maxime Dougados⁵, Filip Van den Bosch⁶ and A.M. van Tubergen⁷, ¹Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁵Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: Spinal mobility is impaired in patients with ankylosing spondylitis (AS) compared to normal subjects. However, the extent of impairment and the relative contribution of…
Abstract Number: 1542 • 2013 ACR/ARHP Annual Meeting
Regular Exercise Is Associated With Better Functional Outcomes In Ankylosing Spondylitis
Lianne S. Gensler¹, John D. Reveille², MinJae Lee³, Mohammad Rahbar⁴, Manouchehr Ardjomand-Hessabi⁵, Matthew A. Brown⁶, Michael H. Weisman⁷ and Michael M. Ward⁸, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ³Medicine, University of Texas Health Science Center at Houston, Houston, TX, ⁴The University of Texas Health Science Center at Houston, Houston, TX, ⁵Medicine, The University of Texas, Health Science Center at Houston, Houston, TX, ⁶Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, Australia, ⁷Rheumatology, Cedars-Sinai Med Ctr, Los Angeles, CA, ⁸Bldg 10 CRC Rm 4-1339, NIAMS/NIH, Bethesda, MD
Background/Purpose: Exercise and physical therapy are the cornerstones of non-pharmacologic therapy in Ankylosing Spondylitis. The long-term association of exercise on function has not been evaluated.…
Abstract Number: 1543 • 2013 ACR/ARHP Annual Meeting
Patients With Ankylosing Spondylitis Are Substantially Undertreated For Hypertension and Hypercholesterolemia
Sjoerd C. Heslinga^1,2,3, Inge A.M. van den Oever¹, Alper M. van Sijl^2,4, Irene E. Van der Horst-Bruinsma^4,5 and Michael. T. Nurmohamed^2,4, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ³Internal Medicine, VU University Medical Center, Amsterdam, Netherlands, ⁴Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁵Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Patients with ankylosing spondylitis (AS) have a decreased life expectancy due to an increased cardiovascular (CV) risk. The general inflammatory process is held responsible…
Abstract Number: 1544 • 2013 ACR/ARHP Annual Meeting
Good Agreement Between The Ankylosing Spondylitis Disease Activity Scores Based On C-Reactive Protein and Erythrocyte Sedimentation Rate
Dilek Solmaz, Pinar Cetin, Ismail Sari, Merih Birlik, Servet Akar, Fatos Onen and Nurullah Akkoc, Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey
Background/Purpose: Recently, ASDAS has been developed as a disease activity measuring tool for ankylosing spondylitis (AS), using a similar methodology to that used for the…
Abstract Number: 1545 • 2013 ACR/ARHP Annual Meeting
Serum Periostin: a New Marker Of Local Bone Formation In Early Inflammatory Back Pain: results From The DESIR Cohort
Karine Briot¹, Simon Paternotte², Didier Borderie³, Corinne Miceli-Richard⁴, Maxime Dougados² and Christian Roux¹, ¹Cochin hospital, Paris Descartes University, Paris, France, ²Cochin Hospital, Paris Descartes University, Paris, France, ³Laboratoire de Biochimie, Hopital Cochin, Paris Descartes University, Pris, France, ⁴Rheumatology Department, Université Paris-Sud 11, Bicêtre Hospital,, Kremlin Bicêtre, France
Background/Purpose: Periostin is a secreted, homodimeric protein that is synthesized by mesenchymal cells of the periosteum, which is involved in osteoblast homeostasis of the periosteum…
Abstract Number: 1546 • 2013 ACR/ARHP Annual Meeting
Patient-Reported Outcomes of Etanercept in Early Non-Radiographic Axial Spondyloarthritis: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Maxime Dougados¹, Wen-Chan Tsai², Diego Luis Saaibi³, Randi Bonin⁴, Jack Bukowski⁵, Ronald Pedersen⁶, Bonnie Vlahos⁷ and Sameer Kotak⁸, ¹Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ²Chung-Ho Memorial Hospital, Kaohsiung, 807, Taiwan, ³MEDICITY S.A.S, Bucaramanga, Santander 681001, Colombia, ⁴Pfizer Inc, Collegeville, PA, ⁵Department of Specialty Care, Pfizer Inc, Collegeville, PA, ⁶Specialty Care, Pfizer Inc, Collegeville, PA, ⁷Department of Specialty Care, Pfizer Inc., Collegeville, PA, ⁸Specialty Care, Pfizer Inc., New York, NY
Background/Purpose: Limited data are available on the efficacy of anti-TNF agents in non-radiographic axial spondyloarthritis (nr-axSpA). This analysis compares the impact of etanercept (ETN) vs…
Abstract Number: 1547 • 2013 ACR/ARHP Annual Meeting
How The Delay In Diagnosis Impacts On The Clinical, Functional and Radiographic Status Of Patients With Ankylosing Spondylitis. Is There a Window Of Opportunity?
luis Alejandro Cayetti¹, Emilce Schneeberger¹, Natalia Zamora², Fernando Sommerfleck² and Gustavo Citera², ¹Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina, ²Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: The delay in diagnosis has deleterious effects in patients with Rheumatoid Arthritis. This fact has not been fully investigated in patients with Ankylosing Spondylitis…
Abstract Number: 1548 • 2013 ACR/ARHP Annual Meeting
Effect Of TNF Inhibitors On Bone Mineral Density In Patients With Ankylosing Spondylitis- a Systematic Review and Meta-Analysis
Nisha Nigil Haroon¹, Jeevitha Srighanthan², Nayef AL Ghanim³, Robert D. Inman^4,5,6,7,8,9 and Angela Cheung¹⁰, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²Osteoporosis Program, University of Toronto, Ontario, ON, Canada, ³Rheumatology, University of Toronto, Toronto, ON, Canada, ⁴Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology, Toronto Western Research Institute. University of Toronto, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁸U of Toronto, Toronto, ON, Canada, ⁹Dept of Medicine/Rheumatology, The Arthritis Program, Toronto Western Hospital and Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁰Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with ankylosing spondylitis (AS) are susceptible to osteoporosis (OP) and have high fracture risk. Currently, no specific strategies are established to treat OP…
Abstract Number: 1549 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Syndesmophytes In Patients With Chronic Back Pain Suspected Of Axial Spondyloarthritis (axSpA) Not Fulfilling The Modified New York (mNY) Criteria
Manouk de Hooge¹, Rosaline van den Berg², Floris van Gaalen², Monique Reijnierse³, Victoria Navarro-Compán², Karen Fagerli⁴, Maureen C. Turina⁵, Maikel van Oosterhout⁶, Roberta Ramonda⁷, Tom Huizinga² and Désiréé van der Heijde¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁶Rheumatology, GHZ Hospital, Gouda, Netherlands, ⁷Rheumatology Unit, University of Padova, Padova, Italy
Background/Purpose: The mNY criteria1, which indicate sacroiliitis of at least grade 2 bilaterally or grade 3 or 4 unilaterally, are used to classify patients as…
Abstract Number: 1550 • 2013 ACR/ARHP Annual Meeting
Validation Of The Ankylosing Spondylitis Disease Activity Score and Effectiveness Of Infliximab In The Treatment Of Ankylosing Spondylitis Over 4 Years: The Canadian Experience
Proton Rahman¹, Denis Choquette², Majed M. Khraishi³, William G. Bensen⁴, Saeed A. Shaikh⁵, Dalton E. Sholter⁶, Maqbool K. Sheriff⁷, Emmanouil Rampakakis⁸, John S. Sampalis⁸, Francois Nantel⁹, Susan M. Otawa¹⁰, Allen J. Lehman¹⁰ and May Shawi¹¹, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ³Nexus Clinical Research, St John's, NF, Canada, ⁴Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁵Medicine, McMaster University, St Catharines, ON, Canada, ⁶Rheumatology Associates, Edmonton, AB, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹Janssen Inc., Toronto, ON, Canada, ¹⁰Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: The efficacy of anti-TNF in the management of Ankylosing Spondylitis (AS) has been demonstrated in numerous controlled clinical trials. The objective of this study…
Abstract Number: 1551 • 2013 ACR/ARHP Annual Meeting
The Minimum Clinically Important Improvement and Patient Acceptable Symptom State In Basdai and BASFI For Patients With Ankylosing Spondylitis
Milla Kviatkovsky¹, Sofia Ramiro², Robert Landewé³, Florence Tubach^4,5, Maxime Dougados⁶ and D. van der Heijde⁷, ¹College of Osteopathic Medicine, Nova Southeastern University, Miami, FL, ²Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ³Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁴Département d'Epidémiologie Biostatistique et Recherche Clinique, APHP, Hôpital Bichat, Paris, France, ⁵INSERM, Universite Paris Diderot, Paris, France, ⁶Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ⁷Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The minimum clinically important improvement (MCII) and patient acceptable symptom state (PASS) are clinically relevant measures that report the patient response and condition. We…
Abstract Number: 1552 • 2013 ACR/ARHP Annual Meeting
Effective Prevention Of New Osteitis On Magnetic Resonance Imaging In Patients With Early Axial Spondyloarthritis During 3 Years Of Continous Treatment With Etanercept – Data Of The Esther Trial
In-Ho Song¹, Kay-Geert A. Hermann², Hildrun Haibel³, Christian Althoff⁴, Denis Poddubnyy³, Joachim Listing⁵, Anja Weiss⁶, Ekkehard Lange⁷, Bruce Freundlich⁸, Martin Rudwaleit⁹ and Joachim Sieper¹⁰, ¹Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ²Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Radiology, Charite Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ⁵German Rheumatism Research Center, Berlin, Germany, ⁶German Rheumatism Research Centre, Berlin, Germany, ⁷BU Specialty Care, Pfizer Pharma AG, Berlin, Germany, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Endokrinologikum, Berlin, Germany, ¹⁰Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin-Franklin, Berlin, Germany
Background/Purpose: In patients with early axial spondyloarthritis (SpA) with a disease duration of
Abstract Number: 1553 • 2013 ACR/ARHP Annual Meeting
Responsiveness Of Health Related Quality Of Life Questionnaires To Treatment With Anti-TNF Therapy In Psoriatic Arthritis
Zahi Touma¹, Arane Thavaneswaran¹, Vinod Chandran² and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Patient-reported outcomes (PRO) on Health Related Quality of Life (HRQoL) are increasingly used to assess responsiveness after treatment. This study aimed to determine the…
Abstract Number: 1554 • 2013 ACR/ARHP Annual Meeting
Real-World Effectiveness Of Infliximab In The Treatment Of Psoriatic Arthritis Over 12 Months: The Canadian Experience
Proton Rahman¹, Majed M. Khraishi², William Bensen³, John T. Kelsall⁴, Brian D. Hanna⁵, Craig Watts⁶, Emmanouil Rampakakis⁷, John S. Sampalis⁷, May Shawi⁸, Susan M. Otawa⁹ and Allen J. Lehman⁹, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Nexus Clinical Research, St John's, NF, Canada, ³St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁵Rheumatology, McMaster University, Ontario, Kitchener, ON, Canada, ⁶Department of Rheumatology, McGill University and Montreal General Hospital, Sainte-Anne-de-Bellevue, QC, Canada, ⁷JSS Medical Research, Montreal, QC, Canada, ⁸Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada, ⁹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: The efficacy of anti-TNF in the management of psoriatic arthritis (PsA) has been demonstrated in numerous controlled clinical trials. Longitudinal observational studies assessing the…
Abstract Number: 1555 • 2013 ACR/ARHP Annual Meeting
Anti-TNF Drug Survival In Psoriatic Arthritis Patients Treated In Ordinary Clinical Practice
Glenn Haugeberg¹, Andreas P. Diamantopoulos¹, Agnete Gulati², Mari Hoff³ and Arthur Kavanaugh⁴, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Rheumatology, St.Olavs Hospital, Trondheim, Norway, ³Rheumatology, St Olavs Hospital, Trondheim, Norway, ⁴University of California San Diego, San Diego, CA
Background/Purpose: The use of TNF-inhibitors in psoriatic arthritis (PsA) has been shown to improve clinical and radiographic outcome in randomized controlled trials (RCT) and shown…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].